Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VIVO Meridian Bioscience (VIVO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Meridian Bioscience Stock (NASDAQ:VIVO) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Get Meridian Bioscience alerts:Sign Up Key Stats Today's Range$33.97▼$33.9750-Day Range$33.00▼$33.9752-Week Range$20.35▼$34.38VolumeN/AAverage Volume973,737 shsMarket Capitalization$1.50 billionP/E Ratio35.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.Read More… Elon knows the truth, which is why they want him silenced (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Meridian Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks23rd Percentile Overall ScoreVIVO MarketRank™: Meridian Bioscience scored higher than 23% of companies evaluated by MarketBeat, and ranked 890th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Meridian Bioscience.Read more about Meridian Bioscience's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.81.Price to Book Value per Share RatioMeridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VIVO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeridian Bioscience does not currently pay a dividend.Dividend GrowthMeridian Bioscience does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.88 Short InterestThere is no current short interest data available for VIVO. News and Social Media0.6 / 5News SentimentN/A Search Interest5 people have searched for VIVO on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Meridian Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Meridian Bioscience is held by insiders.Percentage Held by Institutions89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Meridian Bioscience's insider trading history. Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Stock News HeadlinesWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comMeridian Growth Legacy MERDXOctober 17, 2024 | morningstar.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Vivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comBiomerica, Inc. (BMRA)May 11, 2024 | finance.yahoo.comMeridian Meadows Transitional CareFebruary 8, 2024 | health.usnews.comMeridian Bioscience Earns EcoVadis Bronze Medal in Recognition of Its Dedication to SustainabilityNovember 28, 2023 | benzinga.comSee More Headlines VIVO Stock Analysis - Frequently Asked Questions How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) released its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.03. The business had revenue of $76.20 million for the quarter, compared to the consensus estimate of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%. Does Meridian Bioscience have any subsidiaries? The following companies are subsidiaries of Meridian Bioscience: Exalenz Bioscience. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/12/2021Today11/02/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:VIVO CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.49 Cash Flow$1.78 per share Price / Cash Flow19.13 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares44,010,000Free Float42,996,000Market Cap$1.50 billion OptionableOptionable Beta0.23 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:VIVO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Meridian Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.